Amy Kontorovich, MD, PhD
img_Amy Kontorovich
ASSOCIATE PROFESSOR | Medicine, Cardiology
ASSOCIATE PROFESSOR | Medicine, Medical Genomics
Are you a patient?
Cardiovascular Disease (Heart Disease), Internal Medicine
Kontorovich Research Group
Dr. Kontorovich’s research is focused on developing a better understanding of the relationship between genetic risks and outcomes across several cardiovascular conditions. One of the main areas of interest in the Kontorovich Laboratory is on discovering novel genetic factors that influence risk and outcomes in the inflammatory heart condition, myocarditis. In recent years, our laboratory and others have shown that human genetic variation is important in the phenotypic evolution of myocarditis and may determine the fate of disease in individuals after exposure to viruses that target the heart. Our team investigates these human genetic factors through experiments using human induced pluripotent stem cells, including gene editing techniques (i.e. CRISPR/Cas9), as well as human genomic studies on patients with myocarditis. Another mode of research for our group harnesses the power of large biobanks to identify individuals with genetic risk for specific heart conditions and utilize existing data as well as prospective studies to clarify the natural history and penetrance of these diseases. A major focus of this work is around hereditary transthyretin amyloidosis (hATTR) and cardiac amyloidosis.

MD, State University of NY at Stony Brook School of Medicine

PhD, Stony Brook University Medical Center

Residency, Internal Medicine, Mount Sinai Hospital

Fellowship, Cardiovascular Disease, Mount Sinai Hospital


Selected Publications

Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Anis Barmada, Jon Klein, Anjali Ramaswamy, Nina N. Brodsky, Jillian R. Jaycox, Hassan Sheikha, Kate M. Jones, Victoria Habet, Melissa Campbell, Tomokazu S. Sumida, Amy Kontorovich, Dusan Bogunovic, Carlos R. Oliveira, Jeremy Steele, E. Kevin Hall, Mario Pena-Hernandez, Valter Monteiro, Carolina Lucas, Aaron M. Ring, Saad B. Omer, Akiko Iwasaki, Inci Yildirim, Carrie L. Lucas. Science immunology

Features of Vascular Ehlers-Danlos Syndrome among Biobank Participants Harboring Predicted High-Risk COL3A1 Genotypes. Madeline M. Lui, Mariya Shadrina, Bruce D. Gelb, Amy R. Kontorovich. Circulation. Genomic and precision medicine

Returning integrated genomic risk and clinical recommendations: The eMERGE study. Jodell E. Linder, Aimee Allworth, Harris T. Bland, Pedro J. Caraballo, Rex L. Chisholm, Ellen Wright Clayton, David R. Crosslin, Ozan Dikilitas, Alanna DiVietro, Edward D. Esplin, Sophie Forman, Robert R. Freimuth, Adam S. Gordon, Richard Green, Maegan V. Harden, Ingrid A. Holm, Gail P. Jarvik, Elizabeth W. Karlson, Sofia Labrecque, Niall J. Lennon, Nita A. Limdi, Kathleen F. Mittendorf, Shawn N. Murphy, Lori Orlando, Cynthia A. Prows, Luke V. Rasmussen, Laura Rasmussen-Torvik, Robb Rowley, Konrad Teodor Sawicki, Tara Schmidlen, Shannon Terek, David Veenstra, Digna R. Velez Edwards, Devin Absher, Noura S. Abul-Husn, Jorge Alsip, Hana Bangash, Mark Beasley, Eimear E. Kenny, Sabrina A. Suckiel, Amy Kontorovich, Emily Soper, Gillian Belbin, Girish Nadkarni, Jacqueline Odgis, Joseph Kannry, Michael Preuss, Noura Abul-Husn, Patricia Kovatch, Stephanie Rutledge. Genetics in Medicine

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Kontorovich did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.